4.2.4 Targeted therapies

Some women with ovarian cancer may benefit from the addition of targeted therapies:

  • PARP inhibitors, which inhibit the enzyme poly ADP ribose polymerase – these may typically benefit patients with gene mutations
  • angiogenesis inhibitors – these prevent the growth of blood vessels related to tumours